Organization | Schwarz Pharma

Schwarz Pharma Report issue

Contributed to NME For profit Phase 2 Phase 3

Founded: Mequon WI United States (1985)

Status: Acquired by UCB (2006)

Organization Overview

First Clinical Trial

2002

NCT01761526

First Marketed Drug

1985

prednisone (meticorten)

First NDA Approval

2007

rotigotine (neupro)

Last Known Activity

2011

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sanol GmbH | Schwarz BioSciences GmbH | SCHWARZ PHARMA

Active Ingredients

Marketed Drugs (9)

acetylsalicylic acid (aspirin) (1988)

dexchlorpheniramine maleate (polaramine)

fesoterodine (toviaz) (1998)

hydrocodone (hycodan) (1988)

methimazole (tapazole) (2005)

prednisone (meticorten) (1975)

pseudoephedrine (Benylin)

rotigotine (neupro) (2007 NDA)

theophylline (synophylate)

Drugs in Phase 3 Trials (1)

ferrous glycine sulphate complex (1 trial)

Drugs in Phase 2 Trials (2)

Key: Schwarz Pharma (1) Acquired (1)

rotigotine (neupro) (2 trials)

selodenoson (1 trial)

Indications

Approved Indications

Depression

Parkinson Disease

Restless Legs Syndrome

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Deficiency Diseases (Phase 3)

Psychomotor Agitation (Phase 2)

Restless Legs Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 3